JonesTrading analyst Soumit Roy maintained a Buy rating on Chimerix (CMRX – Research Report) today and set a price target of $5.00. The company’s shares opened today at $0.96.
Roy covers the Healthcare sector, focusing on stocks such as Oncolytics Biotech, Anavex Life Sciences, and Cassava Sciences. According to TipRanks, Roy has an average return of -5.0% and a 27.03% success rate on recommended stocks.
Currently, the analyst consensus on Chimerix is a Strong Buy with an average price target of $7.67, a 698.96% upside from current levels. In a report released on August 16, H.C. Wainwright also maintained a Buy rating on the stock with a $11.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $2.68 and a one-year low of $0.95. Currently, Chimerix has an average volume of 1.15M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.
Read More on CMRX:
- Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in “Cancer Discovery”
- Chimerix announces data highlighting clinical efficacy of ONC201 treatment
- Biotech Alert: Searches spiking for these stocks today
- Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update
- Chimerix reports Q2 EPS (21c), consensus (24c)
